The Hippo

HOME| ADVERTISING | CONTACT US|

Valcyte for Cytomegalovirus in Children Manchester NH

The U.S. Food and Drug Administration has approved Valcyte (valganciclovir hydrochloride) to prevent cytomegalovirus (CMV) disease in children 4 months to 16 years who are undergoing kidney or heart transplant, Swiss drug maker Roche said Monday.

Zimmerman Jeffrey MD
(603) 622-3623
30 Canton Street
Manchester, NH
 
Voroshilova Olga MD
(603) 641-5800
1050 Perimeter Road
Manchester, NH
 
Selleck WM PHYS
(603) 669-9200
4 Elliot Way
Manchester, NH
 
Smith Stephen J PHYS
(603) 669-9200
4 Elliot Way Suite 200
Manchester, NH
 
Butler James S MD
(603) 669-0831
130 Tarrytown Road
Manchester, NH
 
Young Libby Audiologist
(603) 622-3623
30 Canton Street Suite 2
Manchester, NH
 
Tessier Christopher D PHYS
(603) 669-9200
4 Elliot Way
Manchester, NH
 
Amy Christine Stone, MD
(202) 741-3000
1 Elliot Way
Manchester, NH
Specialties
Pediatrics, Internal Medicine-Pediatrics
Gender
Female
Education
Medical School: Univ Of Southern Ca Sch Of Med, Los Angeles Ca 90033
Graduation Year: 2001

Data Provided by:
Deborah Ann Franzek, MD
(603) 633-2637
1 Elliot Way
Manchester, NH
Specialties
Pediatrics, Neonatal-Perinatal Medicine
Gender
Female
Education
Medical School: In Univ Sch Of Med, Indianapolis In 46202
Graduation Year: 1982

Data Provided by:
Peter Michael Clemons
(603) 695-2790
4 Elliot Way
Manchester, NH
Specialty
Pediatric Endocrinology

Data Provided by:
Data Provided by:

Valcyte for Cytomegalovirus in Children

Provided By:

MONDAY, Aug. 31 (HealthDay News) -- The U.S. Food and Drug Administration has approved Valcyte (valganciclovir hydrochloride) to prevent cytomegalovirus (CMV) disease in children 4 months to 16 years who are undergoing kidney or heart transplant, Swiss drug maker Roche said Monday.

CMV disease is a common infection among people who have had an organ transplant. Such patients may be infected with CMV before their surgeries, or be receiving organs that are infected, Roche said in a news release. Children are at increased risk of CMV infection and serious complications when their immune systems are suppressed to prevent rejection of donor organs.

CMV infects about 80 percent of the U.S. population, the company said, and in most cases lies dormant in the body. But when the immune system is weakened, CMV complications could affect the lungs, kidneys, nervous system, liver and gastrointestinal tract -- potentially leading to serious illness or death.

As part of the approval, the FDA sanctioned a new oral liquid form of the drug to allow for easier use in children, Roche said.

The drug has not been evaluated in transplant patients under 4 months of age, the company said.

More information

The FDA has more about this drug's history.

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

®2010 Hippo Press. site by wedu